Uzbekistan Brings Together the International Community at the UN to Strengthen the Fight Against Childhood Cancer
For the first time in the history of the United Nations General Assembly, Uzbekistan held a special event dedicated to “A global movement to improve survival and reduce suffering for children with cancer and other catastrophic diseases”.
The event was hosted by the Government of Uzbekistan, WHO, St. Jude Children’s Research Hospital and Zamin Foundation.
The event was attended by the First Ladies of Azerbaijan, Angola, Vietnam, Guatemala, Serbia, and Türkiye, the spouse of the Prime Minister of Lebanon, the Director-General of WHO, the President of ECOSOC, the President and leadership of St. Jude Children’s Research Hospital, as well as the Ministers of Health of Angola, Armenia, Bangladesh, Mozambique, the Dominican Republic, Nigeria, Kazakhstan, Qatar, the Republic of the Congo, Kyrgyzstan, Malta, Mongolia, the UAE, Peru, Tajikistan, Timor-Leste, Tuvalu, Türkiye, Chad, and Jamaica, along with representatives of healthcare authorities of Hungary, Indonesia, Russia and Tanzania, international organizations, experts and civil society representatives.
The event showcased the results of the Global Initiative for Childhood Cancer and the Global Platform for Access to Childhood Cancer Medicines. Participants reaffirmed their commitment to achieving a 60% survival rate for children with cancer by 2030 through the development of equitable, integrated and locally resourced health systems.
In her address to the participants of the event, chair of the Board of Trustees of the Zamin Foundation Ziroat Mirziyoyeva mentioned:
"Currently, more than 2 billion children worldwide are at risk or suffer from non-communicable diseases. That is almost a third of the world's population. Millions of them are fighting cancer. Despite the achievements of modern medicine, survival rates remain uneven: in developed countries, they are above 80%, while in developing countries, they are below 30%. This is an unacceptable gap. We are obliged to take steps in order to prevent this tragedy!"
In his address, Director-General of the World Health Organization Dr. Tedros Adhanom Ghebreyesus underlined emphasized: “Every child suffering from cancer deserves an equal right to fight for their life, regardless of the country or community they come from. That is why we launched the WHO Global Initiative for Childhood Cancer. The results speak for themselves: the program has helped more than 400 thousand children in 80 low- and middle-income countries”.
Speaking at the event, St. Jude Children’s Research Hospital President James R. Downing stated: “To fulfill our promise that no child should die at the dawn of life, we are laying the foundations of the Global Sickle Cell Disease Initiative, aimed at improving survival rates among children with this condition. I call on every United Nations member state to join both global initiatives. This must become a priority for all countries”.
Children affected by these diseases became special guests of the event. Their touching stories deeply resonated with the participants. From Uzbekistan, young graduate and volunteer of Mehrli maktab, Samira Idrisova, shared her journey.
Uzbekistan is actively contributing to the global movement for children’s health. In recent years, the country has implemented large-scale programs to reduce child cancer mortality, mobilized additional resources, introduced new standards for diagnosis and treatment, and expanded access to medicines.
The country has adopted the National Strategy to Combat Childhood Cancer for 2025–2030, aligned with the WHO’s CureAll framework. The strategy envisions raising the early detection rate to 65%, increasing one-year survival from 34% to 90%, five-year survival to 60%, and ensuring 100% access to specialized multidisciplinary care.
Moreover, an International Academic Hub for Childhood Cancer has been established in Tashkent aimed at facilitating the integration of international standards in diagnostics, specialist training, and innovation, as well as the exchange of best practices and the development of modern clinical research.
The event became an important international platform for the exchange of expertise, demonstration of solidarity and promotion of innovative solutions in addressing one of the most pressing and often underestimated challenges in global healthcare.
The discussion continued with panel sessions focused on sustaining progress in childhood cancer treatment and implementing the global initiative to combat sickle cell anemia.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250926977972/en/
Contacts
For more information, please contact:
Elena Ikaeva
Director of the Department on media and public relations, IPF Zamin
Phone: +998 712052525
+998 935645050
E-mail: e.ikaeva@zaminfoundation.ngo
https://zaminfoundation.ngo/en/about -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fzaminfoundatio
n.ngo%2Fen%2Fabout&esheet=54330372&newsitemid=20250926977972&lan=en-US&anchor=ht
tps%3A%2F%2Fzaminfoundation.ngo%2Fen%2Fabout&index=1&md5=3977c661221018741b0cade
6f464b7f3
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GENESIS Pharma announces a new partnership with Otsuka Pharmaceutical Europe Ltd. for the commercialization of donidalorsen for hereditary angioedema in Central and Eastern Europe15.12.2025 10:00:00 CET | Press Release
ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY GENESIS Pharma, a regional biopharma company focused on the commercialization of innovative medicines in Central and Eastern Europe, announces an exclusive agreementwithOtsuka Pharmaceutical Europe Ltd. (OPEL), the European operation of global healthcare company Otsuka Pharmaceutical Co., Ltd., for donidalorsen. Under the terms of the agreement, GENESIS Pharma will exclusively distribute and commercializedonidalorsen in fourteen markets: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. In November 2025, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for donidalorsen in the routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older. The CHMP opinion is c
BitGo yn Sicrhau Cymeradwyaeth OCC i Drosi i Fanc Ymddiriedolaeth Genedlaethol Siartredig Ffederal13.12.2025 02:13:00 CET | Pressmeddelande
Cyhoeddodd BitGo Holdings, Inc. (“BitGo”), y cwmni seilwaith asedau digidol, heddiw fod Swyddfa Rheolwr yr Arian Cyfred (“OCC”) wedi cymeradwyo ei gais i drosi BitGo Trust Company, Inc., cwmni ymddiriedolaeth siartredig De Dakota, i fanc cenedlaethol o'r enw BitGo Bank & Trust, National Association (N.A.). Gyda chymeradwyaeth OCC heddiw o'i drosi, mae is-gwmni Cwmni Ymddiriedolaeth BitGo bellach yn gweithredu fel BitGo Bank & Trust, National Association (N.A.). Bydd BitGo Bank & Trust, N.A. yn gweithredu o dan un gyfundrefn oruchwylio ffederal unffurf, gan ei alluogi i ddarparu'r eglurder, y llywodraethiant, a'r sicrwydd rheoleiddiol y mae sefydliadau'n eu disgwyl gan ymddiriedolwr a reoleiddir yn ffederal. Mae'r gymeradwyaeth hon yn atgyfnerthu safle BitGo fel sylfaen sefydliadol ar gyfer y system ariannol fodern, gan gyfuno goruchwyliaeth ar lefel banc â'r diogelwch, y cydymffurfiaeth, a'r graddadwyedd sy'n diffinio seilwaith BitGo. O dan siarter y banc cenedlaethol, ac yn amodol ar
FIA, Formula 1 Group and All 11 Race Teams Officially Sign the Ninth Concorde Agreement, Securing Strength and Stability for the Sport in Pivotal Five-Year Agreement12.12.2025 17:10:00 CET | Press Release
The Fédération Internationale de l'Automobile (FIA), the global governing body for motor sport and the federation for mobility organisations worldwide, and Formula 1 Group, the Commercial Rights Holder, have today announced the signing of the Concorde Governance Agreement, a crucial contract defining the regulatory framework and governance terms of the FIA Formula One World Championship until 2030. This follows the announcement in March that the 2026 Commercial Concorde Agreement had been signed by all the teams and Formula 1 Group. Together, these agreements constitute the ninth Concorde Agreement, representing a major step forward in the professionalisation and global development of the sport. First introduced in 1981, the Concorde Agreements are designed to promote sporting fairness, technological innovation and operational excellence, and align all key stakeholders around a shared vision for structured governance and continued growth of the sport. Each iteration of the Concorde Agr
Anabranch Capital Management, LP supports relisting of SmartCraft ASA to Nasdaq Stockholm12.12.2025 16:26:00 CET | Press Release
Reference is made to the stock exchange announcement by SmartCraft ASA ("SmartCraft" or the "Company") on 1 December 2025 regarding the contemplated relisting of SmartCraft from Euronext Oslo Børs to Nasdaq Stockholm (the "Relisting") and the announcement of a cross-border merger to effect the Relisting. Funds managed by Anabranch Capital Management, LP (“Anabranch”) intend to vote in favour of the merger plan resolved by the boards of SmartCraft and its Swedish wholly owned subsidiary, SmartCraft Group AB (publ), to effect the Relisting at the Company's extraordinary general meeting planned for January 2025 (the "EGM"). Anabranch intends to vote with all Anabranch shares held at the Record Date for the EGM in favour of the relisting effected by the merger plan. Funds managed by Anabranch currently hold approximately 15.9 million shares in SmartCraft. Disclaimer: The views expressed are those of the authors and Anabranch Capital Management, LP as of the date referenced and are subject
Mohammed Ben Sulayem Re-Elected as President of the FIA12.12.2025 15:49:00 CET | Press Release
The Fédération Internationale de l’Automobile (FIA), the global governing body for motor sport and the federation for mobility organisations worldwide, today confirms that Mohammed Ben Sulayem has been re-elected as President of the FIA, following the election of his Presidential List by the General Assembly in Tashkent, Republic of Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251212213181/en/ President Mohammed Ben Sulayem now begins his second four-year term, having overseen a period of significant renewal and stabilisation for the organisation since his initial election in 2021. Over the past four years, the FIA has undergone a wide-ranging transformation, improving governance, operations and restoring the financial health of the federation. These changes have strengthened the FIA’s position as the world’s governing body for motorsport and the leading authority on safe, sustainable, and affordable mobility.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom